Skip to main
DXCM
DXCM logo

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 56%
Buy 31%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

DexCom is well-positioned for long-term growth, particularly with the upcoming commercialization of its G7 15-day continuous glucose monitoring system. The company's strategy includes integration with insulin pumps from Insulet and Tandem, enhancing its product offerings and attracting a broader patient base. Additionally, continued adoption of DexCom products among both insulin-using and non-insulin-using diabetic populations supports a positive financial outlook.

Bears say

DexCom's financial outlook is tempered by a downward revision of revenue and adjusted EPS projections for 2026, with estimates now at $5.386 billion and $2.69, respectively, a decrease from previous figures of $5.646 billion and $2.91. The company's anticipated growth rate is also declining, with the new projection reflecting only a 16.4% year-over-year increase, compared to an earlier expectation of 22.0%. Additionally, potential regulatory delays pose further risks to future revenue generation, contributing to a negative outlook on the stock.

DexCom (DXCM) has been analyzed by 16 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 31% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 16 analysts, DexCom (DXCM) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.